reported that FOXC2 promotes melanoma progression via several oncogenic pathways, including xenobiotic metabolism, oxidative stress response and interferon responsiveness, as well as is a prognostic indicator of patient response to chemotherapy and immunotherapy (67). This evidence concerns the gene FOXC2 and melanoma.